The finder
Pick what you want to change. See who actually measured it.
Every other tool like this gives you a compound and a match score. Those scores are not measured. Ours does not exist. What you get instead is what was actually measured and where: trials in people first with the participant count, then the animal and cell work kept separate, then what people using it report, and the trials that found nothing, counted rather than dropped.
82 of the 444 compounds here have never been through a trial in people. That is worth knowing and it is not a verdict: a molecule nobody can patent has no sponsor to pay for a trial, so a thin human record is usually a fact about money rather than about the compound. Where that is the case, this says so and shows you what does exist.
What are you trying to change?
Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive, so you can see where the evidence is before you choose.
Or start from the compounds
Somebody handed you a stack. What is actually known about it?
Add what you are looking at and you get every outcome those compounds have been measured for in people, and then the longer list of the ones they have not.
Losing weight
How much weight did people actually lose?
The most heavily measured outcome on this site, and the one where the number in the trial and the number in the advert are furthest apart.
39,505 people · 98 human studies · 68 compounds
- 4,623 people2 studies
3,417 adults: 20.4% weight loss at 68 weeks versus 3.0% with placebo (treatment-policy estimand); 22.7% by trial-product estimand.
New England Journal of Medicine, 2025 · 3,417 people
1,206 patients with type 2 diabetes: 13.7% weight loss at 68 weeks versus 3.4% with placebo.
New England Journal of Medicine, 2025 · 1,206 people
- 4,418 people2 studies
2,539 adults without diabetes: mean weight change at 72 weeks of -15.0% (5 mg), -19.5% (10 mg) and -20.9% (15 mg) versus -3.1% with placebo.
New England Journal of Medicine, 2022 · 2,539 people
1,879 patients over 40 weeks: all tirzepatide doses were noninferior and superior to semaglutide 1 mg for HbA1c, with greater weight loss (up to -5.5 kg more at 15 mg).
New England Journal of Medicine, 2021 · 1,879 people
- 3,755 people2 studies
REDEFINE 1, 3,417 participants. Estimated mean weight change from baseline to week 68 was 20.4% on cagrilintide-semaglutide against 3.0% on placebo, a difference of 17.3 percentage points. Gastrointestinal adverse events affected 79.6% of the combination group against 39.9% on placebo. A developed, co-formulated...
New England Journal of Medicine, 2025 · 3,417 people
338 adults with obesity. Least-squares mean weight change at 48 weeks was 8.7% on 1 mg, 17.1% on 4 mg, 22.8% on 8 mg and 24.2% on 12 mg, against 2.1% on placebo. At 12 mg, 83% lost 15% or more of body weight against 2% on placebo. The most common adverse events were gastrointestinal, dose-related, and partially...
New England Journal of Medicine, 2023 · 338 people
- 3,731 people1 study
3,731 adults without diabetes: mean weight loss of 8.4 kg with liraglutide 3.0 mg vs 2.8 kg with placebo at 56 weeks; 63.2% vs 27.1% lost at least 5%. Basis of the Saxenda obesity approval.
New England Journal of Medicine, 2015 · 3,731 people
- 3,675 people3 studies
1,961 adults without diabetes: mean body weight change of -14.9% at 68 weeks with semaglutide 2.4 mg versus -2.4% with placebo; 86.4% lost 5% or more.
New England Journal of Medicine, 2021 · 1,961 people
1,407 adults: -18.7% body weight at 72 weeks on 7.2 mg versus -15.6% on 2.4 mg and -3.9% on placebo; dysaesthesia reported by 22.9% on 7.2 mg.
The Lancet Diabetes & Endocrinology, 2025 · 1,407 people
307 adults randomized 2:1: oral semaglutide 25 mg produced -13.6% body weight at week 64 versus -2.2% with placebo (treatment-policy estimand); GI adverse events in 74.0% vs 42.2%.
New England Journal of Medicine, 2025 · 307 people
- 3,417 people2 studies
REDEFINE 1. 3,417 participants randomised to cagrilintide-semaglutide, semaglutide alone, cagrilintide alone or placebo. Estimated mean body weight change to week 68 was 20.4% on the combination against 3.0% on placebo, a difference of 17.3 percentage points. Gastrointestinal adverse events affected 79.6% of the...
New England Journal of Medicine, 2025 · 3,417 people
STEP 1. Semaglutide 2.4 mg weekly gave a 14.9% mean weight change at 68 weeks against 2.4% on placebo. This is the single-agent comparator that the combination is measured against.
New England Journal of Medicine, 2021 · no headcount in the line
- 3,127 people3 studies
Phase 3, 3,127 adults: 11.2% weight loss at 72 weeks on 36 mg versus 2.1% with placebo (treatment-regimen estimand); 36% lost 15% or more.
New England Journal of Medicine, 2025 · 3,127 people
Phase 2: 9.4% to 14.7% weight loss at 36 weeks across doses versus 2.3% with placebo; GI events mostly mild to moderate.
New England Journal of Medicine, 2023 · no headcount in the line
April 1, 2026 approval announcement; quotes 12.4% (27.3 lb) weight loss on the highest dose in ATTAIN-1 by the efficacy estimand.
Eli Lilly press release, 2026 · no headcount in the line
- 2,004 people3 studies
Phase 3a, 1,206 patients: -13.7% body weight at 68 weeks with CagriSema vs -3.4% with placebo; 73.5% reached HbA1c of 6.5% or lower.
New England Journal of Medicine, 2025 · 1,206 people
706 participants over 26 weeks: cagrilintide monotherapy produced 6.0% to 10.8% weight loss across doses vs 3.0% with placebo; 4.5 mg beat liraglutide 3.0 mg (10.8% vs 9.0%).
The Lancet, 2021 · 706 people
92 adults with type 2 diabetes over 32 weeks: body weight change of -15.6% with CagriSema vs -5.1% with semaglutide alone and -8.1% with cagrilintide alone (NCT04982575).
The Lancet, 2023 · 92 people
- 1,341 people2 studies
Phase 3 in 731 adults: both mazdutide doses were superior to dulaglutide 1.5 mg for HbA1c and produced 3.8 to 5.8 percentage points more weight loss at 28 weeks.
Nature, 2026 · 731 people
Phase 3 in 610 adults: mean weight change of minus 10.1% (4 mg) and minus 12.6% (6 mg) versus plus 0.5% on placebo at week 32.
New England Journal of Medicine, 2025 · 610 people
- 901 people1 study
Phase 2, randomised, double-blind, placebo-controlled, dose-ranging. 901 participants treated with at least one dose, 512 in the type 2 diabetes cohort and 389 in the obesity cohort. Terminated early for safety reasons after routine data and monitoring review, with planned analyses modified before unblinding. HbA1c...
Diabetes, Obesity and Metabolism, 2025 · 901 people
- 899 people3 studies1 found nothing
834 adults with type 2 diabetes and BMI 25 or more on metformin, randomised to cotadutide 100 mcg (100), 200 mcg (256) or 300 mcg (256), placebo (110) or open-label liraglutide 1.8 mg (110) for 54 weeks. HbA1c and weight fell against placebo at weeks 14 and 54 (all P below 0.001). Weight loss at 300 mcg exceeded...
Diabetes Care, 2021 · 834 people
Phase 2a, 65 adults with type 2 diabetes and overweight or obesity, 49 days of daily cotadutide (50 to 300 mcg) or placebo. Postprandial glucose area under the curve fell 21.5 percent against a 6.3 percent rise on placebo (P below 0.001); weight fell 3.41 percent against 0.08 percent (P equals 0.002); postprandial...
Journal of Clinical Endocrinology and Metabolism, 2020 · 65 people
found nothingPhase 2a energy balance study; 12 cotadutide and 7 placebo completers over 42 days. Weight change minus 4.0 percent against minus 1.4 percent (P equals 0.011); energy intake fell 41.3 percent against placebo; energy expenditure by doubly labelled water did not differ (1.0 percent, P equals 0.784). Weight loss was...
Diabetes, Obesity and Metabolism, 2024 · no headcount in the line
- 741 people2 studies
Multicentre double-blind placebo-controlled phase 3 in 427 non-diabetic Chinese adults, randomised 2:1 to 0.2 mg subcutaneously three times daily or placebo for 16 weeks. Mean body weight change was minus 6.0 percent against minus 2.4 percent, a difference of 3.6 percentage points. 58.2 percent versus 25.4 percent...
Diabetes, Obesity and Metabolism, 2024 · 427 people
Retrospective observational data on 314 Chinese patients with type 2 diabetes treated between 2017 and 2018. After three months, weight fell 10.05 kg and glycated haemoglobin 2.87 percentage points, with 84.96 percent losing at least 5 percent of body weight. These figures are far larger than the randomised phase 3...
Obesity Science and Practice, 2019 · 314 people
- 684 people2 studies
52-week trial in 480 patients with type 1 diabetes: pramlintide lowered HbA1c by 0.67% versus 0.16% for placebo at week 13, with weight loss rather than gain and no rise in severe hypoglycemia.
Diabetes Care, 2002 · 480 people
16 weeks in 204 obese subjects without insulin: placebo-corrected weight loss of 3.7% (3.6 kg), showing the amylin pathway's appetite effect that later informed cagrilintide.
Journal of Clinical Endocrinology and Metabolism, 2007 · 204 people
- 664 people2 studies
664 Chinese adults: 9.1% to 13.2% weight loss at 40 weeks versus 0.1% with placebo; 87% on 2.4 mg lost at least 5%.
The Lancet Diabetes and Endocrinology, 2025 · 664 people
March 6, 2026 approval; 15.4% mean weight loss at 48 weeks on 2.4 mg (placebo-adjusted 15.1%).
Sciwind Biosciences press release, 2026 · no headcount in the line
- 603 people2 studies
46-week trial in 387 adults without diabetes: mean weight change of minus 14.9% at 4.8 mg weekly versus minus 2.8% on placebo; gastrointestinal adverse events were common.
The Lancet Diabetes and Endocrinology, 2024 · 387 people
Phase 3 in 216 adults: 84% on survodutide 6 mg versus 24% on placebo achieved at least a 30% liver-fat reduction, with minus 12.2% versus minus 1.0% body weight at 48 weeks.
Nature Medicine, 2026 · 216 people
- 592 people2 studies
592 participants: 12.3% to 16.2% weight loss at 52 weeks in the obesity cohort versus 2.5% with placebo (treatment-policy estimand), with no plateau.
New England Journal of Medicine, 2025 · 592 people
Up to about 20% weight loss (efficacy estimand) in obesity and about 17% with type 2 diabetes at 52 weeks; Phase 3 MARITIME program initiated.
Amgen press release, 2025 · no headcount in the line
- 507 people1 study
507 adults: weight change at 48 weeks was -17.8 kg for high-dose combination, -14.2 kg semaglutide alone, -9.3 kg bimagrumab alone, -3.3 kg placebo.
Nature Medicine, 2026 · 507 people
- 493 people2 studies
March 5, 2026: 493 participants; up to 10.7% mean weight loss at 42 weeks versus 1.7% with placebo; Phase 3 to start later in 2026.
Zealand Pharma press release, 2026 · 493 people
Well tolerated with mostly mild GI events and clinically relevant weight loss; supports development for weight management.
Diabetes, Obesity and Metabolism, 2026 · no headcount in the line
- 340 people2 studies
Double-blind placebo-controlled phase 2b trial, 340 Chinese adults with overweight or obesity, mean age 33.1 years and mean weight 95.6 kg, randomised across five dose groups. Mean percentage change in body weight from baseline to week 30 ranged from minus 9.75 to minus 16.69 percent with bofanglutide against minus...
Signal Transduction and Targeted Therapy, 2026 · 340 people
The earlier and much smaller weight-management trial under the development code. Sixty participants enrolled, 46 completed. Least-squares mean change in body weight was minus 9.36 percent for GZR18 against 6.68 percent for placebo in part A, and minus 17.8 percent weekly and minus 12.8 percent every two weeks against...
Cell Reports Medicine, 2026 · no headcount in the line
- 338 people1 study
338 adults over 48 weeks: least-squares mean body weight change of -24.2% at 12 mg, -22.8% at 8 mg and -17.1% at 4 mg versus -2.1% with placebo.
New England Journal of Medicine, 2023 · 338 people
- 336 people1 study
336 patients at 82 US sites: HbA1c fell 0.78% (10 mcg twice daily) and 0.40% (5 mcg) versus a 0.08% rise on placebo, with dose-dependent weight loss of up to 2.8 kg.
Diabetes Care, 2005 · 336 people
- 273 people1 study
273 treatment-naive adults at 30 Chinese centres, randomised 1:1 to 150 micrograms weekly or placebo for 24 weeks, then all on active drug to week 52. At week 24 glycated haemoglobin fell 1.36 percentage points against 0.63 on placebo, a difference of 0.73 points. 50.4 percent reached below 7.0 percent against 14.2...
The Lancet Regional Health Western Pacific, 2024 · 273 people
- 235 people2 studies
235 adults with BMI 28 to 40 randomised across four doses and placebo. At week 26 mean weight change was -9.36% on 180 mg against -2.50% on placebo (placebo-adjusted -6.87%); gastrointestinal events were the most common and were mostly mild to moderate.
Nature Communications, 2026 · 235 people
About 11% weight loss at 50 weeks; HbA1c down 1.5% to 1.7%.
Kailera press release, 2026 · no headcount in the line
- 204 people1 study
Phase 2, 204 participants actual, started 27 June 2024, completed 12 February 2025, status TERMINATED. Primary outcomes were mean percent change in body weight for the once-daily and twice-daily azelaprag arms. The registry's stated reason for stopping, verbatim: dosing of both study drugs was discontinued due to...
ClinicalTrials.gov NCT06515418 (STRIDES), BioAge Labs, 2025 · 204 people
How this is counted
Human studies only. Animal and test-tube work never enters this ranking, because the question you asked was about a person.
A compound is listed for an outcome only when a citation on its own page states that outcome and reports a result for it. Naming it is not enough: a paper that measures testosterone and reports a result about something else does not count as testosterone evidence, which is a mistake this tool made on its first run and no longer makes.
People counts are read out of the study lines themselves and are deliberate undercounts. Where a line states no number, the study still counts as a study and adds nothing to the headcount. Counts are never added across compounds, because the same person can appear in more than one trial.
Ranking is by people measured. That is a fact about the evidence, not a judgement about the compound, and it is the only ordering this site will defend. A compound at the top of a list is the most studied, which is not the same as the best.
Nothing here is advice, and nothing here is a recommendation to take anything.